Q-omics provides the consensus-scored MIR514B profile across patient tissues and cancer cell-line models. MIR514B expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR514B is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, MIR514B RNA expression shows 6,864 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where MIR514B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR514B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR514B survival associations across molecular data types. MIR514B RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR514B RNA expression–survival associations across cancer types. High MIR514B expression shows unfavorable associations in LUAD, BRCA and HNSC, but favorable associations in KIRC, COAD and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR514B RNA expression.
This table summarizes MIR514B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR514B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR514B shows lower tumor expression in KICH, COAD, CHOL and LIHC and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher MIR514B RNA expression in tumor versus normal tissue (log2 FC = +1.185, t-test p < 0.001).
This table shows molecular features associated with MIR514B in patient tissues and cancer cell lines. In patient samples, MIR514B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
